Synteract Launches Rare Disease Institute
Synteract, a CRO partnering with biotech and pharma companies to bring new medicines to market, has launched the Synteract Rare Disease Institute. The program incorporates lectures, webinars, interactive discussions, videos, and industry literature. The Synteract Rare Disease Institute will cover a wide variety of topics including patient perspectives, bioethics, regulatory requirements, customer engagement, patient advocacy and more.
Derek Ansel, Director, Rare, Orphan, and Pediatrics, who leads the program, says, “I’m thrilled to announce the creation of the Synteract Rare Disease Institute, designed specifically for rare and orphan diseases. Our goal has been to provide a comprehensive rare disease program that spans from disease indications, innovative delivery models, to patient perspectives. The Synteract Rare Disease Institute gives our employees a foundation in rare disease development and encourages proactive understanding and exploration of this growing area of clinical research.”
Synteract’s history of working with pioneering biotech companies aided the natural evolution of the institute. Synteract has considerable experience working on rare and orphan disease projects, which enables the cultivation and expansion of offerings designed to meet the needs of its biotech partners.
Vice President for Rare, Orphan and Pediatrics Lisa Dilworth adds, “The deployment of the Synteract Rare Disease Institute signifies our corporate commitment to achieving excellence and maintaining quality in the rare disease area. This program builds on the passion and dedication our employees have demonstrated for rare disease research while fostering collaboration and innovation from the executive level to the end user.
As trials in rare disease have seen rapid acceleration in recent years, Synteract’s Rare Disease Institute has been established to meet the growing needs of the clinical research industry and of the patients who suffer from rare diseases.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
